导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.21% | 3017/4772 |
| 近一周 | -0.35% | 1108/5490 |
| 近一月 | -2.84% | 1824/5407 |
| 近一季 | -3.92% | 2774/5201 |
| 近半年 | -4.71% | 2505/4918 |
| 近一年 | -0.89% | 2883/4355 |
| 近两年 | 43.07% | 1770/2950 |
| 近三年 | 30.89% | 988/2241 |
| 成立以来 | 74.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.76% 2898/4961 |
11.70% 2305/5312 |
- - |
- - |
| 2025 | 18.73% 2287/4813 |
1.16% 1683/3635 |
2.59% 1476/4076 |
14.66% 2886/4524 |
-0.23% 2426/4813 |
| 2024 | 22.20% 391/3463 |
5.15% 399/2808 |
0.44% 608/3014 |
15.74% 1637/3129 |
-0.03% 1300/3463 |
| 2023 | -7.88% 956/2656 |
4.64% 897/2280 |
-4.43% 1167/2385 |
-2.18% 634/2515 |
-5.83% 1520/2655 |
| 2022 | -19.75% 892/2207 |
-15.24% 1029/1919 |
8.64% 343/2016 |
-13.13% 838/2113 |
0.31% 1508/2208 |
| 2021 | 4.49% 575/1822 |
-1.36% 477/1255 |
7.13% 699/1330 |
-3.21% 619/1466 |
2.16% 672/1822 |
| 2020 | 35.52% 412/1250 |
-9.02% 650/1028 |
14.11% 569/1067 |
15.01% 242/1164 |
13.51% 354/1184 |
| 2019 | 9.59% 731/1092 |
4.27% 733/739 |
0.96% 141/788 |
0.85% 451/850 |
3.22% 843/918 |
| 2018 | -1.43% 59/834 |
- - |
1.33% 24/631 |
-0.09% 168/660 |
-2.82% 22/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 海富通沪深300指数增强A VS. 长安沪深300非周期A(740101) |